Tovorafenib Suppliers & Bulk Manufacturers
Available Forms: Oral suspension
Available Strengths: 25 mg/ml
Reference Brands: Ojemda (USA)
Category:
Oncology Cancer Care
Tovorafenib is available in Oral suspension
and strengths such as 25 mg/ml.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Tovorafenib is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Tovorafenib can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Tovorafenib is an oral targeted therapy used for the treatment of glioma, particularly in patients with tumors driven by abnormal RAF signaling. It is a type II RAF kinase inhibitor designed to selectively block aberrant RAF activity, which plays a critical role in tumor cell growth and survival. By inhibiting this pathway, tovorafenib helps slow disease progression and supports tumor control in affected patients.
Marketed under the brand name Ojemda, tovorafenib is used in oncology care where precise molecular targeting is essential. It has demonstrated clinical benefit in patients with glioma and is administered orally, offering a convenient treatment option compared with invasive therapies. As a targeted agent, tovorafenib requires careful patient selection and monitoring to optimize therapeutic outcomes.
Common adverse reactions associated with tovorafenib therapy include rash, fatigue, hair color changes, headache, nausea, vomiting, dry skin, constipation, fever, and upper respiratory tract infections. Laboratory abnormalities may include changes in phosphate, hemoglobin, liver enzymes, creatinine phosphokinase, electrolytes, and blood cell counts. Due to these effects, routine clinical and laboratory monitoring is recommended during treatment. Tovorafenib represents an important advancement in precision oncology for glioma management.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing